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the commercial monoclonal antibody. Collectively, we demon-
strate that the rationally designed small molecules can be potent
and specific drugs for anti-cancer therapy.
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Numerous studies have shown that high-dose chemotherapy
and autologous hematopoietic stem cell transplantation (AHSCT)
led to a profound and long-lasting state of immunodeficiency
characterized by persisting low levels of T cells in hemoblastosis
patients. Well-timed T-cell reconstitution is crucial for early
restoration of anti-infectious and anti- tumor immune response.
Lymphocyte recovery is mediated through the two main mecha-
nisms – a homeostatic proliferation of T cells and generation of
new naive T cells via thymopoiesis. It is known, that homeostatic
proliferation is important for the restoration of T cell count in
immune competent host during the 1st year following AHSCT.
Thymus begins to fill up T cell repertoire approximately from
the 6th month following AHSCT.
We have investigated dynamics of CD4+FOXP3+ Treg recovery
following AHSCT and possible relationship between Tregs and
clinical outcomes since the suppressive activity of Tregs under
lymphopenic conditions may influence on peripheral expansion
of T cells. Thymic activity following AHSCT has been evaluated
by measuring amounts of CD4+ CD45RA+CD31+ naı¨ve T cells,
i.e. ‘‘recent thymic emigrants” (RTEs).109 patients with non-
Hodgkin’s lymphomas, Hodgkin’s lymphoma and multiple mye-
loma underwent AHSCT in 2009–2014. The content of circulating
CD4+FOXP3+ Tregs and CD4+CD45RA+CD31+ T cells was
evaluated using flow cytometry before AHSCT, at the day of
engraftment, and following 6 and 12 months.
Pre-transplant count of CD4+FOXP3+ Tregs was significantly
higher compared to healthy controls (5.4 ± 2.9 vs 3.8 ± 1.9%;
pU = 0.011; here and below data presented as Mean ± SD). Percent-
age of Tregs restored rapidly and reached initially high level at the
time of engraftment, and then subsequently decreased within a
year until it lowered to healthy donors‘ values. CD4+FOXP3+ Tregs
at the time of engraftment were increased in patients with
relapse or progression of disease within 6 and 12 months
following AHSCT compared to non-relapsed patients (11.0 ± 6.1
vs 6.2 ± 3.0%; pU = 0.016, and 10.1 ± 5.2 vs 6.1 ± 3.8%; pU = 0.008).
Pre-transplant count of CD4+CD45RA+CD31+ T cells was signifi-
cantly lower compared to healthy controls (17.1 ± 11.4 vs 30.3
± 11.2%, pU = 0.0005) and did not reach donors‘ values following
12 month (23.1 ± 13.5%, pU = 0.032). Relapsed patients had the
same quantity of RTEs as the patients with remission within
the 1st year following AHSCT. There was no any significant
association between RTEs and Tregs counts.
Surprisingly, we have found high levels of circulating CD4
+CD45RA- T cells co-expressing CD31 molecule in patients before
AHSCT, since this molecule is infrequent on memory subsets in
healthy controls (20.7 ± 12.0 vs 8.2 ± 2.1%,pU < 0.00001). Relative
amount of CD4+CD45RA-CD31+ T cells highly correlated with
CD4+CD45RO+CD31+ population (rS=0.72; p < 0.00001). The count
of CD4+CD45RA-CD31+ T cells recovered intensively and reached
the pre-transplant level within the 1st month following AHSCT,
and remained at the same level throughout the follow-up. There
were no any differences in relative count of CD4+CD45RA-CD31+
T cells between patients with early relapse and remission during
the 1st post-transplant year.
Our data of Tregs reconstitution may confirm the earlier
assumption that the presence of Tregs during the period of
immune recovery preserves optimal T cell receptors diversity.
However, the excess of these cells leads to the inhibition of
proliferative activity and immune response and is associated with
early relapse. Conversely, relatively slow recovery of RTEs
determines theirlack of influence on survival within the 1st
post-transplant year.
The biological role and the way of appearance of CD31
molecule on T cell memory subset (CD4+CD45RA- and/or CD4
+CD45RO+) still remain unclear. Further studies are required to
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Background: Gastric cancer (GC) remains one of the most
important gastrointestinal cancers worldwide. The incidence
and mortality rate from GC in Russia is higher in comparison with
other European countries and USA. It should be noted that
riskometry for the GC doesn’t exist. Parallel assessment of
pepsinogen I (PG I), pepsinogen II (PG II), PG I/PG II ratio and
gastrin-17 (G-17), as well as antibodies to Helicobacter pylori is an
exact and validated set of stomach-specific biomarkers that
reflect the extent and grade of gastric atrophy as a main prema-
lignant condition for GC.
Aim: To study the diagnostic and predicting value of
biomarkers of atrophic gastritis (AG) in retro-prospective cohort
case-control study in Siberian population.
Object and methods: General population sample was surveyed
in Novosibirsk in 2003–2005 (10.000 subjects aged 45–69 years).
Each serum sample was deeply frozen and stored. In 2008 and
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